CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Feb 24, 2026, 4:00 PM EST

CNBX Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Sep - Aug.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '25 Aug '25 Aug '24 Aug '23 Aug '22 Aug '21
Net Income
-0.39-0.31-0.7-3.71-3.72-3.19
Depreciation & Amortization
--0.070.160.20.22
Loss (Gain) From Sale of Investments
--0.092.73-0.01-0.2
Stock-Based Compensation
--0.140.180.730.03
Other Operating Activities
0.080.040.020.050.720.71
Change in Accounts Receivable
000.09-0.010.12-0.01
Change in Accounts Payable
0.130.10.040.490.28-0.05
Operating Cash Flow
-0.18-0.17-0.24-0.11-1.68-2.49
Capital Expenditures
---0--0-0
Sale of Property, Plant & Equipment
--0.11-0.03-
Investment in Securities
---0.02-0.65
Investing Cash Flow
--0.110.020.030.65
Short-Term Debt Issued
-0.160.030.10.392.46
Total Debt Issued
0.170.160.030.10.392.46
Net Debt Issued (Repaid)
0.170.160.030.10.392.46
Financing Cash Flow
0.170.160.030.10.392.46
Foreign Exchange Rate Adjustments
-----0-
Net Cash Flow
-0.01-0.01-0.10.01-1.270.61
Free Cash Flow
-0.18-0.17-0.25-0.11-1.68-2.49
Free Cash Flow Margin
---188.71%-27.43%-5610.68%-
Free Cash Flow Per Share
-0.00-0.00-0.01-0.01-1.38-2.16
Levered Free Cash Flow
-0.11-0.09-0.030.23-0.51-1.48
Unlevered Free Cash Flow
-0.06-0.07-0.020.23-0.51-1.48
Change in Working Capital
0.130.10.130.470.41-0.06
Updated Nov 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.